JP2020533439A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533439A5 JP2020533439A5 JP2020513549A JP2020513549A JP2020533439A5 JP 2020533439 A5 JP2020533439 A5 JP 2020533439A5 JP 2020513549 A JP2020513549 A JP 2020513549A JP 2020513549 A JP2020513549 A JP 2020513549A JP 2020533439 A5 JP2020533439 A5 JP 2020533439A5
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- immunogenic composition
- protein
- composition according
- protein conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 claims 26
- 229920001282 polysaccharide Polymers 0.000 claims 26
- 239000005017 polysaccharide Substances 0.000 claims 26
- 230000002163 immunogen Effects 0.000 claims 13
- 239000002671 adjuvant Substances 0.000 claims 7
- 102000014914 Carrier Proteins Human genes 0.000 claims 6
- 108010078791 Carrier Proteins Proteins 0.000 claims 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 6
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 4
- 101800002949 Diphtheria toxin fragment B Proteins 0.000 claims 3
- 229960002885 histidine Drugs 0.000 claims 3
- 229960000814 tetanus toxoid Drugs 0.000 claims 3
- 208000034628 Celiac artery compression syndrome Diseases 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- BBWBEZAMXFGUGK-UHFFFAOYSA-N bis(dodecylsulfanyl)-methylarsane Chemical compound CCCCCCCCCCCCS[As](C)SCCCCCCCCCCCC BBWBEZAMXFGUGK-UHFFFAOYSA-N 0.000 claims 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims 2
- 238000000569 multi-angle light scattering Methods 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101710082714 Exotoxin A Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 108010031071 cholera toxoid Proteins 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
Claims (26)
- 以下の構造を有する繰り返し単位を含む精製された多糖体：
- 前記多糖体が５〜５０００の繰り返し単位を有する、請求項１に記載の多糖体。
- 前記多糖体が５０〜１５００の繰り返し単位を有する、請求項１に記載の多糖体。
- 前記多糖体が、ＭＡＬＳにより決定される１０ｋＤａ〜２０００ｋＤａの平均分子量を有する、請求項１に記載の多糖体。
- 前記多糖体が、ＭＡＬＳにより決定される５０ｋＤａ〜１５００ｋＤａの平均分子量を有する、請求項１に記載の多糖体。
- 以下の構造の繰り返し単位を有する多糖体から生成された活性化多糖体であって、
前記多糖体は、化学試薬によって活性化されて、リンカーまたはキャリアタンパク質へのコンジュゲーションのための反応基を生成する、活性化多糖体。 - 前記多糖体が過ヨウ素酸塩によって活性化される、請求項６に記載の活性化多糖体。
- 以下の構造のいくつかの繰り返し単位を有する、請求項７に記載の活性化多糖体：
- 以下の構造の繰り返し単位を有し、
キャリアタンパク質にコンジュゲートされている多糖体を有する多糖体−タンパク質コンジュゲート。 - 前記キャリアタンパク質が、ＣＲＭ１９７、ジフテリア毒素フラグメントＢ（ＤＴＦＢ）、ＤＴＦＢ Ｃ８、ジフテリアトキソイド（ＤＴ）、破傷風トキソイド（ＴＴ）、ＴＴのフラグメントＣ、百日咳トキソイド、コレラトキソイド、Ｅ．ｃｏｌｉ ＬＴ、Ｅ．ｃｏｌｉ ＳＴ、またはシュードモナス・エルギノーサ由来の外毒素Ａである、請求項９に記載の多糖体−タンパク質コンジュゲート。
- 前記キャリアタンパク質がＣＲＭ１９７である、請求項１０に記載の多糖体−タンパク質コンジュゲート。
- 前記多糖体−タンパク質コンジュゲートが１０００ｋＤａ〜１０，０００ｋＤａの分子量を有する、請求項１１に記載の多糖体−タンパク質コンジュゲート。
- 前記多糖体−タンパク質コンジュゲートが、０．４〜２．０の多糖体対タンパク質比を有する、請求項１１に記載の多糖体−タンパク質コンジュゲート。
- 前記タンパク質が、アラビニトール糖の第２の炭素を介して前記多糖体にコンジュゲートされている、請求項１３に記載の多糖体−タンパク質コンジュゲート。
- 請求項９から１４のいずれか一項に記載の多糖体−タンパク質コンジュゲートと、薬学的に許容される担体とを含む免疫原性組成物。
- ＣＲＭ１９７にコンジュゲートされた、ストレプトコッカス・ニューモニエの血清型１、２、３、４、５、６Ａ、６Ｂ、６Ｃ、６Ｄ、７Ｂ、７Ｃ、７Ｆ、８、９Ｎ、９Ｖ、１０Ａ、１１Ａ、１２Ｆ、１４、１５Ａ、１５Ｂ、１５Ｃ、１６Ｆ、１７Ｆ、１８Ｃ、１９Ａ、１９Ｆ、２０、２１、２２Ａ、２２Ｆ、２３Ａ、２３Ｂ、２３Ｆ、２７、２８Ａ、３１、３３Ｆ、３４、３５Ａ、３５Ｂ、３５Ｆおよび３８のうちの少なくとも１つに由来する莢膜多糖体を含む多糖体−タンパク質コンジュゲートをさらに含む、請求項１５に記載の免疫原性組成物。
- 存在する場合０．８〜８μｇ／ｍＬの多糖体を含有する血清型６Ｂ多糖体を除いて、０．４〜４μｇ／ｍＬの各多糖体と、多糖体の総量の約０．５倍〜３倍の量のＣＲＭ１９７キャリアタンパク質とを含有するように製剤化される、請求項１６に記載の免疫原性組成物。
- １５０ｍＭ塩化ナトリウムと、２０ｍＭ Ｌ−ヒスチジン緩衝液と、０．０５〜２％ｗ／ｖの界面活性剤とをさらに含む、請求項１７に記載の免疫原性組成物。
- アジュバントをさらに含む、請求項１８に記載の免疫原性組成物。
- 前記アジュバントがアルミニウムベースのアジュバントである、請求項１９に記載の免疫原性組成物。
- 前記アジュバントが、リン酸アルミニウム、硫酸アルミニウムおよび水酸化アルミニウムからなる群から選択される、請求項２０に記載の免疫原性組成物。
- 前記アジュバントがリン酸アルミニウムである、請求項２１に記載の免疫原性組成物。
- 前記リン酸アルミニウムアジュバントが０．０５〜０．５ｍｇ／ｍＬの濃度で存在する、請求項２２に記載の免疫原性組成物。
- １５０ｍＭ塩化ナトリウムと、２０ｍＭ Ｌ−ヒスチジン緩衝液と、０．０５〜２％ｗ／ｖの界面活性剤とをさらに含む、請求項２３に記載の免疫原性組成物。
- ストレプトコッカス・ニューモニエ莢膜多糖体に対する免疫応答を誘発するための、請求項１５から２４のいずれか一項に記載の免疫原性組成物。
- 前記免疫原性組成物が、存在する場合４μｇである血清型６Ｂ多糖体を除いて、２μｇの各多糖体と、約３２μｇのＣＲＭ１９７キャリアタンパク質と、０．１２５ｍｇのリン酸アルミニウムアジュバントと、１５０ｍＭ塩化ナトリウムと、２０ｍＭ Ｌ−ヒスチジン緩衝液と、０．２％ｗ／ｖのＰＳ−２０とを含有するように製剤化された単一の０．５ｍＬ用量である、請求項２５に記載の免疫原性組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024019152A JP2024056835A (ja) | 2017-09-07 | 2024-02-13 | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555461P | 2017-09-07 | 2017-09-07 | |
| US62/555,461 | 2017-09-07 | ||
| US201862645252P | 2018-03-20 | 2018-03-20 | |
| US62/645,252 | 2018-03-20 | ||
| PCT/US2018/049308 WO2019050815A1 (en) | 2017-09-07 | 2018-09-04 | ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019152A Division JP2024056835A (ja) | 2017-09-07 | 2024-02-13 | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020533439A JP2020533439A (ja) | 2020-11-19 |
| JP2020533439A5 true JP2020533439A5 (ja) | 2021-08-19 |
| JPWO2019050815A5 JPWO2019050815A5 (ja) | 2023-11-27 |
| JP7438102B2 JP7438102B2 (ja) | 2024-02-26 |
Family
ID=65634964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513549A Active JP7438102B2 (ja) | 2017-09-07 | 2018-09-04 | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
| JP2024019152A Pending JP2024056835A (ja) | 2017-09-07 | 2024-02-13 | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019152A Pending JP2024056835A (ja) | 2017-09-07 | 2024-02-13 | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3678654A4 (ja) |
| JP (2) | JP7438102B2 (ja) |
| KR (1) | KR20200051004A (ja) |
| CN (2) | CN111093650B (ja) |
| AU (2) | AU2018328037B2 (ja) |
| BR (1) | BR112020004509A8 (ja) |
| CA (1) | CA3074708A1 (ja) |
| MX (1) | MX2020002555A (ja) |
| WO (1) | WO2019050815A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| US11197921B2 (en) | 2017-01-31 | 2021-12-14 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| KR20240011879A (ko) | 2017-02-24 | 2024-01-26 | 머크 샤프 앤드 돔 엘엘씨 | 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체의 면역원성의 증진 |
| US11400162B2 (en) | 2017-02-24 | 2022-08-02 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
| US11524076B2 (en) | 2017-09-07 | 2022-12-13 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| AU2018328035B2 (en) | 2017-09-07 | 2024-03-07 | Chitrananda Abeygunawardana | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| EP3678655A4 (en) | 2017-09-07 | 2021-05-05 | Merck Sharp & Dohme Corp. | ANTIPNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN POLYSACCHARIDE-CARRIER PROTEIN IMMUNOGENIC CONJUGATES |
| KR20200051005A (ko) | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
| AR114154A1 (es) | 2017-12-06 | 2020-07-29 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos |
| SG11202006388SA (en) | 2018-02-05 | 2020-07-29 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| WO2019203599A1 (ko) | 2018-04-18 | 2019-10-24 | 에스케이바이오사이언스 주식회사 | 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체 |
| KR20210002641A (ko) | 2018-04-30 | 2021-01-08 | 머크 샤프 앤드 돔 코포레이션 | 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법 |
| JP2021522288A (ja) | 2018-04-30 | 2021-08-30 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法 |
| CA3123414A1 (en) | 2018-12-19 | 2020-06-25 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2022035816A1 (en) * | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| JPH04506662A (ja) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
| NZ239643A (en) | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| CA2129899C (en) | 1992-02-11 | 2011-01-04 | James J. Mond | Dual carrier immunogenic construct |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| JP3506431B2 (ja) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ジフテリア毒素受容体結合領域 |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| ES2231770T3 (es) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | Nuevos plasmidos para la produccion de proteina crm y toxina difterica. |
| EP0720485B1 (en) | 1993-09-22 | 2003-11-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| US5866135A (en) | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1996034609A1 (en) * | 1994-12-05 | 1996-11-07 | The Biomembrane Institute | Myeloglycan |
| EP0814833B1 (en) | 1995-03-22 | 2003-05-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| AU754256C (en) | 1997-12-23 | 2004-05-20 | Pfizer Ireland Pharmaceuticals | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines |
| US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| AU781027B2 (en) | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| WO2001098334A2 (en) | 2000-06-20 | 2001-12-27 | Shire Biochem Inc. | Streptococcus antigens |
| MXPA03005386A (es) | 2000-12-28 | 2004-04-20 | Wyeth Corp | Proteina protectora recombinante de streptococcus pneumoniae. |
| MXPA03009415A (es) | 2001-04-16 | 2004-01-29 | Wyeth Corp | ESTRUCTURAS NOVEDOSAS DE LECTURA ABIERTA DE STREPTOCOCCUS PNEUMONIAE QUE CODIFICAN ANTIGENOS DE POLIPePTIDOS Y USOS DE LAS MISMAS. |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
| ES2295836T3 (es) | 2003-03-13 | 2008-04-16 | Glaxosmithkline Biologicals S.A. | Procedimiento de purificacion de citolisina bacteriana. |
| WO2004083251A2 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA2604363C (en) | 2005-04-08 | 2015-06-16 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| ES2922132T3 (es) | 2007-03-23 | 2022-09-08 | Wyeth Llc | Procedimiento abreviado de purificación para la producción de polisacáridos capsulares de Streptococcus pneumoniae |
| TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| KR20140038517A (ko) | 2011-06-13 | 2014-03-28 | 머크 샤프 앤드 돔 코포레이션 | 천연 또는 돌연변이 형태의 디프테리아 독소의 정제 방법 |
| PL3363806T3 (pl) | 2012-12-20 | 2022-12-19 | Pfizer Inc. | Sposób glikokoniugacji |
| EP2829612A1 (en) * | 2013-07-25 | 2015-01-28 | Technische Universität München | Method for producing exopolysaccharides, products and uses thereof |
| NZ759686A (en) * | 2014-01-21 | 2023-07-28 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN105934251A (zh) * | 2014-01-21 | 2016-09-07 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
| EP3166981A4 (en) * | 2014-07-09 | 2018-03-07 | Cadena Bio, Inc. | Oligosaccharide compositions and methods for producing thereof |
| RU2721128C2 (ru) * | 2015-07-21 | 2020-05-18 | Пфайзер Инк. | Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения |
| EP3334437A1 (en) * | 2015-08-25 | 2018-06-20 | Kaleido Biosciences, Inc. | Glycan compositions and uses thereof |
| WO2017083520A1 (en) * | 2015-11-13 | 2017-05-18 | Cadena Bio, Inc. | Animal therapeutic and feed compositions and methods of use |
| EP3436061A4 (en) * | 2016-03-31 | 2019-12-04 | Liffey Biotech Limited | Saccharide-polypeptide-conjugate compositions and methods of use thereof |
| WO2019050818A1 (en) * | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | METHODS OF FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN |
| AU2018328035B2 (en) * | 2017-09-07 | 2024-03-07 | Chitrananda Abeygunawardana | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| EP3678655A4 (en) * | 2017-09-07 | 2021-05-05 | Merck Sharp & Dohme Corp. | ANTIPNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN POLYSACCHARIDE-CARRIER PROTEIN IMMUNOGENIC CONJUGATES |
| KR20200051005A (ko) * | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
| AR114154A1 (es) * | 2017-12-06 | 2020-07-29 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos |
-
2018
- 2018-09-04 BR BR112020004509A patent/BR112020004509A8/pt unknown
- 2018-09-04 CN CN201880058217.4A patent/CN111093650B/zh active Active
- 2018-09-04 CN CN202410181167.6A patent/CN118063638A/zh active Pending
- 2018-09-04 JP JP2020513549A patent/JP7438102B2/ja active Active
- 2018-09-04 AU AU2018328037A patent/AU2018328037B2/en active Active
- 2018-09-04 CA CA3074708A patent/CA3074708A1/en active Pending
- 2018-09-04 WO PCT/US2018/049308 patent/WO2019050815A1/en active Application Filing
- 2018-09-04 MX MX2020002555A patent/MX2020002555A/es unknown
- 2018-09-04 EP EP18853342.6A patent/EP3678654A4/en active Pending
- 2018-09-04 KR KR1020207009614A patent/KR20200051004A/ko not_active Application Discontinuation
-
2024
- 2024-02-13 JP JP2024019152A patent/JP2024056835A/ja active Pending
- 2024-03-07 AU AU2024201518A patent/AU2024201518A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533439A5 (ja) | ||
| JP2020533438A5 (ja) | ||
| JP2020533437A5 (ja) | ||
| JP2020533442A5 (ja) | ||
| JP7132954B2 (ja) | 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン | |
| TWI720448B (zh) | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 | |
| Khatun et al. | An overview of structural features of antibacterial glycoconjugate vaccines that influence their immunogenicity | |
| HRP20211288T1 (hr) | Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati | |
| ES2546186T3 (es) | Procedimiento de fabricación de vacunas | |
| RU2634405C2 (ru) | Иммуногенная композиция | |
| HRP20120278T1 (hr) | Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom | |
| IL276230B2 (en) | A multivalent pneumococcal protein-polysaccharide conjugate preparation | |
| HRP20110685T1 (hr) | Cjepivo od konjugata pneumokoknog polisaharida | |
| IL276229B2 (en) | A multivalent pneumococcal protein-polysaccharide conjugate preparation | |
| JP2018516962A5 (ja) | ||
| BRPI0408167B1 (pt) | Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais | |
| US10729763B2 (en) | Mixtures of polysaccharide-protein pegylated compounds | |
| CN113164581A (zh) | 纯化的肺炎链球菌荚膜多糖 | |
| JPWO2019050815A5 (ja) | ||
| US20240000958A1 (en) | Novel carriers and conjugation methods | |
| RU2020112314A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель | |
| Zou et al. | Preparation of glycoconjugate vaccines | |
| RU2020112308A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель | |
| RU2023120100A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель | |
| RU2020112309A (ru) | Пневмококковые полисахариды и их применение в иммуногенных конъюгатах полисахарид-белок-носитель |